1 Small-Cap Stock with Competitive Advantages and 2 Facing Headwinds
By:
StockStory
December 02, 2025 at 23:33 PM EST
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats. The downside that can come from buying these securities is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. Keeping that in mind, here is one small-cap stock that could be the next 100 bagger and two that may have trouble. Two Small-Cap Stocks to Sell:Jamf (JAMF)Market Cap: $1.73 billion With its name playfully derived from "Just Another Management Framework," Jamf (NASDAQ: JAMF) provides software that helps organizations deploy, manage, and secure Apple devices across their workforce while maintaining a seamless user experience. Why Does JAMF Worry Us?
Jamf is trading at $12.97 per share, or 2.3x forward price-to-sales. Read our free research report to see why you should think twice about including JAMF in your portfolio. OceanFirst Financial (OCFC)Market Cap: $1.09 billion Tracing its roots back to 1902 when it began serving coastal New Jersey communities, OceanFirst Financial (NASDAQ: OCFC) operates as a regional bank holding company that provides commercial and consumer banking services primarily in New Jersey and surrounding metropolitan areas. Why Should You Sell OCFC?
At $19.08 per share, OceanFirst Financial trades at 0.7x forward P/B. To fully understand why you should be careful with OCFC, check out our full research report (it’s free for active Edge members). One Small-Cap Stock to Watch:Clover Health (CLOV)Market Cap: $1.29 billion Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ: CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care. Why Should CLOV Be on Your Watchlist?
Clover Health’s stock price of $2.49 implies a valuation ratio of 35.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members. Stocks We Like Even MoreIf your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear. Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. More NewsView More
3 Stocks Poised to Benefit From Google’s AI Breakthough ↗
Today 18:22 EST
Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026 ↗
Today 17:23 EST
3 Stocks You’ll Wish You Bought Before 2026 ↗
Today 16:43 EST
Via MarketBeat
Via MarketBeat
Tickers
CRWD
Okta: Excuses to Sell Vs. Reasons to Buy ↗
Today 14:45 EST
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
